IL145891A0 - Methods and compositions for modulating an immune response - Google Patents

Methods and compositions for modulating an immune response

Info

Publication number
IL145891A0
IL145891A0 IL14589100A IL14589100A IL145891A0 IL 145891 A0 IL145891 A0 IL 145891A0 IL 14589100 A IL14589100 A IL 14589100A IL 14589100 A IL14589100 A IL 14589100A IL 145891 A0 IL145891 A0 IL 145891A0
Authority
IL
Israel
Prior art keywords
modulating
compositions
methods
immune response
immune
Prior art date
Application number
IL14589100A
Other languages
English (en)
Original Assignee
Childrens Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Medical Center filed Critical Childrens Medical Center
Publication of IL145891A0 publication Critical patent/IL145891A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
IL14589100A 1999-04-15 2000-04-17 Methods and compositions for modulating an immune response IL145891A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12977299P 1999-04-15 1999-04-15
PCT/US2000/010340 WO2000063241A2 (fr) 1999-04-15 2000-04-17 Procedes et compositions de modulation d'une reponse immunitaire

Publications (1)

Publication Number Publication Date
IL145891A0 true IL145891A0 (en) 2002-07-25

Family

ID=22441531

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14589100A IL145891A0 (en) 1999-04-15 2000-04-17 Methods and compositions for modulating an immune response

Country Status (8)

Country Link
EP (1) EP1175223A2 (fr)
JP (1) JP2003517284A (fr)
AU (1) AU773350B2 (fr)
BR (1) BR0009791A (fr)
CA (1) CA2370129A1 (fr)
IL (1) IL145891A0 (fr)
MX (1) MXPA01010332A (fr)
WO (1) WO2000063241A2 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0101973D0 (en) * 2001-01-25 2001-03-14 Statens Seruminstitut Improved in vitro diagnostic method of detecting a cell-mediated immune response
JP2002221520A (ja) * 2001-01-29 2002-08-09 Sumitomo Chem Co Ltd 免疫型の予測方法
US7202044B2 (en) 2001-05-09 2007-04-10 Biovision Ag Method for detecting a progressive, chronic dementia disease, and corresponding peptides and detection agents
HUP0400005A3 (en) * 2001-05-17 2012-09-28 Serono Lab Use of osteopontin for the treatment and/or prevention of neurologic diseases
GB0116185D0 (en) * 2001-07-02 2001-08-22 Imp College Innovations Ltd Substances
US7241873B2 (en) 2001-09-25 2007-07-10 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Recombinant anti-osteopontin antibody and use thereof
JP2005535313A (ja) * 2002-06-25 2005-11-24 アベンティス・ファーマスーティカルズ・インコーポレイテツド オステオポンチン、オリゴデンドロサイトおよび髄鞘形成
AU2003258127A1 (en) 2002-08-06 2004-02-23 Diadexus, Inc. Compositions and methods relating to ovarian specific genes and proteins
WO2004103403A1 (fr) * 2003-05-23 2004-12-02 Immuno-Biological Laboratories Co., Ltd. Inhibiteur d'activation cellulaire immunocompetente et son utilisation
WO2005100562A1 (fr) * 2004-04-12 2005-10-27 Gene Techno Science Co., Ltd. ARNsi POUR L'OSTÉOPONTINE
CA2667263C (fr) * 2006-10-26 2016-11-08 Gene Techno Science Co., Ltd. Anticorps dirige contre rgd dans une sequence d'acides amines d'une proteine de matrice extracellulaire et procede de fabrication et utilisation de celui-ci
CN101293916A (zh) * 2007-04-24 2008-10-29 上海国健生物技术研究院 骨桥蛋白的功能表位、与其特异性结合的单克隆抗体及用途
US8614296B2 (en) 2008-04-24 2013-12-24 Gene Techno Science Co., Ltd. Humanized antibodies specific for amino acid sequence RGD of an extracellular matrix protein and the uses thereof
KR20110010134A (ko) * 2008-06-06 2011-01-31 가부시키가이샤 진 테크노 사이언스 인간·오스테오폰틴 ｓｉＲＮＡ
US8617829B2 (en) 2009-09-24 2013-12-31 Gene Techno Science Co., Ltd. Humanized antibodies specific for amino acid sequence RGD of an extracellular matrix protein and the uses thereof
EP2788015A1 (fr) * 2011-12-07 2014-10-15 Arla Foods Amba Variantes d'ostéopontine destinées à être utilisées dans la suppression ou la prévention de la croissance tumorale, et compositions les contenant
CN105407910B (zh) * 2013-07-05 2019-12-03 阿拉食品公司 用于增强免疫应答的哺乳动物乳骨桥蛋白
WO2016112193A1 (fr) * 2015-01-07 2016-07-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Utilisation d'inhibiteurs à base de peptides de la voie stat3-il10 pour le traitement d'une infection bactérienne et d'une maladie granulomateuse
WO2019207355A1 (fr) 2018-04-25 2019-10-31 Health And Happiness (H&H) Hong Kong Limited Combinaisons d'ostéopontine et de 2'-fucosyllactose destinées à être utilisées en tant que médicaments
WO2022226049A1 (fr) * 2021-04-20 2022-10-27 University Of Cincinnati Adjuvant vaccinal pour maladies infectieuses
CN115707772A (zh) * 2021-08-18 2023-02-21 澳门大学 一种诱导剂、巨噬细胞及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056405A1 (fr) * 1997-06-10 1998-12-17 Whitehead Institute For Biomedical Research Procede utilisant l'osteopontine pour moduler une reponse immunitaire

Also Published As

Publication number Publication date
BR0009791A (pt) 2002-01-08
MXPA01010332A (es) 2002-09-18
WO2000063241A9 (fr) 2002-03-28
JP2003517284A (ja) 2003-05-27
CA2370129A1 (fr) 2000-10-26
AU4357500A (en) 2000-11-02
WO2000063241A2 (fr) 2000-10-26
AU773350B2 (en) 2004-05-20
WO2000063241A3 (fr) 2001-05-10
EP1175223A2 (fr) 2002-01-30

Similar Documents

Publication Publication Date Title
IL145891A0 (en) Methods and compositions for modulating an immune response
EP1176948A4 (fr) Compositions et methodes antinauseeuses
AUPQ419099A0 (en) Novel compositions and methods
EP1196192A4 (fr) Procede d'amelioration d'une reponse immunitaire
EP1030654A4 (fr) Preparation d'omeprazole
EP1056456A4 (fr) Compositions et procedes d'utilisation du r-lansoprazole
AU7968398A (en) Compositions, devices, kit and method for modulating immune response
IL138207A0 (en) Methods and devices for modulating the immune response
EP1056457A4 (fr) Compositions de s-lansoprazole et procedes d'utilisation
AU2002309486A8 (en) Methods and compositions for modulating the immune system of animals
AU7474100A (en) Methods and compositions for reducing immune response
EP1073333A4 (fr) Compositions a base de s-rabeprazole et procedes
AU2273397A (en) Methods and compositions for modulating an immune response
PL343432A1 (en) Methods and devices for modulating the immune response
GB9922135D0 (en) Compositions and uses
GB0318113D0 (en) ›-Secretase enzyme compositions and methods
IL140574A0 (en) Methods and compositions for modulating spermatogenesis
AU2002248646A1 (en) Compositions and methods for modulating an immune response
AU4866201A (en) Compositions and methods for use in modulating immune system function
AU8513698A (en) Methods and compositions for designing vaccines
AU8408798A (en) Methods and compositions for inhibiting the proinflammatory response
EP1073332A4 (fr) Compositions a base de r-rabeprazole et procedes
GB9807062D0 (en) Immune response
EP1071325A4 (fr) Compositions et methodes de vaccination specifique de l'antigene
AU2001229601A1 (en) Method and composition for modulating an immune response